Diagnostic value of Doppler ultrasound parameters combined with MMP-11 in early breast cancer and benign breast diseases

Ren,Hui; Shen,Zhipeng; Shen,Jirui; Zhang,Yu; Zhang,Yunhua

doi:10.3892/ol.2020.11676

Diagnostic value of Doppler ultrasound parameters combined with MMP-11 in early breast cancer and benign breast diseases

Authors:
- Hui Ren
- Zhipeng Shen
- Jirui Shen
- Yu Zhang
- Yunhua Zhang
View Affiliations

Affiliations: Department of Ultrasound, Liaocheng Third People's Hospital, Liaocheng, Shandong 252000, P.R. China, Department of Ultrasound, Liaocheng People's Hospital, Liaocheng, Shandong 252000, P.R. China
Published online on: May 28, 2020 https://doi.org/10.3892/ol.2020.11676
Pages: 1028-1032
Copyright: © Ren et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diagnostic value of Doppler ultrasound parameters combined with matrix metalloproteinase‑11 (MMP‑11) in early breast cancer and benign breast diseases were investigated. A total of 72 patients who underwent color Doppler ultrasound examination in Liaocheng Third People's Hospital from March 2015 to August 2018 were collected as research subjects, and the blood of 60 healthy subjects who underwent physical examinations was collected. The expression level of MMP‑11 in serum of breast cancer patients was evaluated, and the diagnostic value of color Doppler ultrasound combined with MMP‑11 in breast cancer was assessed. The diagnostic results of color Doppler ultrasound and the imaging characteristics of breast cancer patients were recorded. The results of biopsy and ultrasound were compared. The expression level of MMP‑11 in serum of breast cancer patients was significantly higher than that of healthy subjects (P<0.05). The AUC of MMP‑11 was 0.735, the sensitivity was 66.67%, and the specificity was 86.11%. Among the 72 patients, there were 41 patients diagnosed with breast cancer by serum MMP‑11 examination, 38 patients diagnosed by ultrasound examination, 33 patients diagnosed by combined diagnosis, and 30 patients diagnosed by pathology biopsy. The pathological biopsy was used as the gold standard. The diagnostic efficacy of ultrasound combined with mammography examination was significantly better than the other two single examinations (P<0.050). In conclusion, Doppler ultrasound parameters combined with MMP‑11 has a high diagnostic accordance rate in the diagnosis of breast cancer. At the same time, different diagnostic methods combined with the clinical manifestations of patients can improve the diagnostic accuracy, which is worthy of providing reference and advice for future clinical practice.

View Figures

View References

1	DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA and Jemal A: Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin. 66:31–42. 2016. View Article : Google Scholar : PubMed/NCBI
2	Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, et al: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 study. Lancet Oncol. 16:25–35. 2015. View Article : Google Scholar : PubMed/NCBI
3	Coughlin SS and Ekwueme DU: Breast cancer as a global health concern. Cancer Epidemiol. 33:315–318. 2009. View Article : Google Scholar : PubMed/NCBI
4	Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, et al CLEOPATRA Study Group, : Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 372:724–734. 2015. View Article : Google Scholar : PubMed/NCBI
5	Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, et al PALOMA3 Study Group, : Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 373:209–219. 2015. View Article : Google Scholar : PubMed/NCBI
6	Yu QC, Verheyen EM and Zeng YA: Mammary development and breast cancer: A Wnt perspective. Cancers (Basel). 8:652016. View Article : Google Scholar
7	Collignon J, Lousberg L, Schroeder H and Jerusalem G: Triple-negative breast cancer: Treatment challenges and solutions. Breast Cancer (Dove Med Press). 8:93–107. 2016.PubMed/NCBI
8	Guo R, Lu G, Qin B and Fei B: Ultrasound imaging technologies for breast cancer detection and management: A Review. Ultrasound Med Biol. 44:37–70. 2018. View Article : Google Scholar : PubMed/NCBI
9	Cheng CW, Yu JC, Wang HW, Huang CS, Shieh JC, Fu YP, Chang CW, Wu PE and Shen CY: The clinical implications of MMP-11 and CK-20 expression in human breast cancer. Clin Chim Acta. 411:234–241. 2010. View Article : Google Scholar : PubMed/NCBI
10	Clark A and Fallowfield LP: Breast cancer. CRC Press. 2014.
11	Tadayyon H, Sadeghi-Naini A, Wirtzfeld L, Wright FC and Czarnota G: Quantitative ultrasound characterization of locally advanced breast cancer by estimation of its scatterer properties. Med Phys. 41:0129032014. View Article : Google Scholar : PubMed/NCBI
12	Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH and Lee KH; Community of population-based Regional cancer registries, : Cancer statistics in Korea: Incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat. 49:292–305. 2017. View Article : Google Scholar : PubMed/NCBI
13	Poortmans PM, Collette S, Kirkove C, Van Limbergen E, Budach V, Struikmans H, Collette L, Fourquet A, Maingon P, Valli M, et al EORTC Radiation Oncology, ; Breast Cancer Groups: Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med. 373:317–327. 2015. View Article : Google Scholar : PubMed/NCBI
14	Tutt A, Ellis P, Kilburn L, Gilett C, Pinder S and Abraham J: Abstract S3-01: the TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012). Cancer Res. 75 (Suppl 9):S3–S4. 2015.
15	Basset P, Bellocq JP, Lefebvre O, Noël A, Chenard MP, Wolf C, Anglard P and Rio MC: Stromelysin-3: A paradigm for stroma-derived factors implicated in carcinoma progression. Crit Rev Oncol Hematol. 26:43–53. 1997. View Article : Google Scholar : PubMed/NCBI
16	Bianchini G, Balko JM, Mayer IA, Sanders ME and Gianni L: Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 13:674–690. 2016. View Article : Google Scholar : PubMed/NCBI
17	Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, Podhajcer OL, Chenard MP, Rio MC and Chambon P: A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature. 348:699–704. 1990. View Article : Google Scholar : PubMed/NCBI
18	Okada A, Saez S, Misumi Y and Basset P: Rat stromelysin 3: cDNA cloning from healing skin wound, activation by furin and expression in rat tissues. Gene. 185:187–193. 1997. View Article : Google Scholar : PubMed/NCBI
19	Tan J, Buache E, Alpy F, Daguenet E, Tomasetto CL, Ren GS and Rio MC: Stromal matrix metalloproteinase-11 is involved in the mammary gland postnatal development. Oncogene. 33:4050–4059. 2014. View Article : Google Scholar : PubMed/NCBI
20	Schönbeck U, Mach F, Sukhova GK, Atkinson E, Levesque E, Herman M, Graber P, Basset P and Libby P: Expression of stromelysin-3 in atherosclerotic lesions: Regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med. 189:843–853. 1999. View Article : Google Scholar : PubMed/NCBI
21	Andarawewa KL, Motrescu ER, Chenard MP, Gansmuller A, Stoll I, Tomasetto C and Rio MC: Stromelysin-3 is a potent negative regulator of adipogenesis participating to cancer cell-adipocyte interaction/crosstalk at the tumor invasive front. Cancer Res. 65:10862–10871. 2005. View Article : Google Scholar : PubMed/NCBI
22	Motrescu ER and Rio MC: Cancer cells, adipocytes and matrix metalloproteinase 11: A vicious tumor progression cycle. Biol Chem. 389:1037–1041. 2008. View Article : Google Scholar : PubMed/NCBI
23	Tan J, Buache E, Chenard MP, Dali-Youcef N and Rio MC: Adipocyte is a non-trivial, dynamic partner of breast cancer cells. Int J Dev Biol. 55:851–859. 2011. View Article : Google Scholar : PubMed/NCBI
24	Hadler-Olsen E, Winberg JO and Uhlin-Hansen L: Matrix metalloproteinases in cancer: Their value as diagnostic and prognostic markers and therapeutic targets. Tumour Biol. 34:2041–2051. 2013. View Article : Google Scholar : PubMed/NCBI
25	Benson CS, Babu SD, Radhakrishna S, Selvamurugan N and Ravi Sankar B: Expression of matrix metalloproteinases in human breast cancer tissues. Dis Markers. 34:395–405. 2013. View Article : Google Scholar : PubMed/NCBI